Article Text

PDF

Failure of captopril to reverse the renal crisis of scleroderma
  1. E. A. Brown1,
  2. G. A. Macgregor1,
  3. R. N. Maini2
  1. 1Department of Medicine, Charing Cross Hospital Medical School, Fulham Palace Road, London W6
  2. 2Kennedy Institute of Rheumatology, 6 Bute Gardens, London W6 7DW

    Abstract

    Captopril, an oral inhibitor of angiotensin converting enzyme, has recently been described as causing a dramatic reversal of the renal crisis in scleroderma in 2 patients1. We report here 2 patients with scleroderma, hypertension, and rapidly deteriorating renal function who were given captopril. Despite good blood pressure control, captopril had no effect on renal function, both patients requiring long-term haemodialysis.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.